NanoViricides

NNVC · NYSE American

$1.48−$0.22 (−12.94%)TodayMarket closed · Oct 21, 4:28 AM ET

Prev close $1.70

Latest news

Press releaseOct 20, 8:45 AM ETACCESS Newswire
NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials
Press releaseOct 13, 8:45 AM ETACCESS Newswire
Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides
Press releaseOct 5, 8:45 AM ETACCESS Newswire
NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
Press releaseSep 29, 8:45 AM ETACCESS Newswire
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials
Press releaseSep 28, 8:45 AM ETACCESS Newswire
Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides
Press releaseSep 23, 8:30 AM ETACCESS Newswire
Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
Press releaseSep 15, 9:25 AM ETACCESS Newswire
Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in  DR Congo with 48% Crude Fatality Rate, Says NanoViricides
Press releaseSep 15, 9:00 AM ETGlobe Newswire
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
NewsSep 8, 8:37 AM ET
NanoViricides Says Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For Current Bundibugyo Ebolavirus And Other Ebola Viruses In DR Congo Registered In Pan African Clinical Trials Registry Database
Press releaseSep 8, 8:30 AM ETACCESS Newswire
Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo
Press releaseAug 31, 8:30 AM ETACCESS Newswire
While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles
NewsAug 28, 12:43 PM ET
World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency
Press releaseAug 18, 8:30 AM ETACCESS Newswire
The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon
Press releaseAug 10, 8:30 AM ETACCESS Newswire
NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
Press releaseJul 28, 8:30 AM ETACCESS Newswire
NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial
NewsJul 24, 8:05 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
Press releaseJul 22, 8:30 AM ETACCESS Newswire
As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola
Press releaseJun 22, 9:30 AM ETACCESS Newswire
NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo
Press releaseJun 15, 8:30 AM ETACCESS Newswire
As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo
Press releaseJun 8, 8:30 AM ETACCESS Newswire
As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies
NewsMay 27, 1:05 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsMay 27, 5:10 AM ETAvi Kapoor
Why Semtech Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket
Press releaseMay 26, 8:30 AM ETACCESS Newswire
In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides
Press releaseMay 18, 8:30 AM ETACCESS Newswire
Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides
Press releaseMay 11, 8:30 AM ETACCESS Newswire
Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides
Press releaseMay 4, 8:30 AM ETACCESS Newswire
NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA
Press releaseApr 21, 8:30 AM ETACCESS Newswire
Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides
Press releaseApr 7, 8:30 AM ETACCESS Newswire
Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides
Press releaseApr 1, 8:30 AM ETACCESS Newswire
Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides
NewsMar 5, 7:05 AM ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Press releaseNov 14, 8:30 AM ETACCESS Newswire
NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2
NewsNov 10, 4:07 PM ET
12 Health Care Stocks Moving In Monday's After-Market Session
NewsNov 10, 8:35 AM ET
NanoViricides Receives DRC Approval To Start Phase II Trial Of NV-387 For MPox Treatment
Press releaseNov 10, 8:30 AM ETACCESS Newswire
NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo
NewsOct 29, 8:52 AM ET
NanoViricides Announces CEO Dr. Anil Diwan Shares That Company's Lead Drug, NV-387, Demonstrated Potent Activity Against The Measles Virus In Cell Cultures And A Humanized Animal Model, Protecting Lung Tissue And Significantly Extending Survival—from 7.4 Days In Untreated Animals To 17 Days In Treated Ones
Press releaseOct 29, 8:45 AM ETACCESS Newswire
Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials

Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides

NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials

Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides

Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides

Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViricides

A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat

NanoViricides Says Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For Current Bundibugyo Ebolavirus And Other Ebola Viruses In DR Congo Registered In Pan African Clinical Trials Registry Database

Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo

While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles

World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency

The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon

NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak

NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial

12 Health Care Stocks Moving In Friday's Pre-Market Session

As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola

NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo

As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo

As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies

12 Health Care Stocks Moving In Wednesday's Intraday Session

Why Semtech Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket

In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides

Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides

Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides

NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA

Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides

Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides

Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides

12 Health Care Stocks Moving In Thursday's Pre-Market Session

NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2

12 Health Care Stocks Moving In Monday's After-Market Session

NanoViricides Receives DRC Approval To Start Phase II Trial Of NV-387 For MPox Treatment

NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo

Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive

Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in  DR Congo with 48% Crude Fatality Rate, Says NanoViricides